Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic
We found high treatment satisfaction with LA-CAB+RPV in a diverse population. Participants reported moderate injection pain, which improved with time. Results suggest injectable LA-CAB+RPV will be met with acceptability across diverse participant populations.
Authors
- Sarah E. Pérez
- Casey Morgan Luc (ORCID: https://orcid.org/0000-0003-3669-9821)
- Gregory Huhn (ORCID: https://orcid.org/0000-0002-4699-5467)
- Mark S. Dworkin (ORCID: https://orcid.org/0000-0003-0974-8368)
- Kara Herrera (ORCID: https://orcid.org/0009-0008-4424-6359)
- Blake Max (ORCID: https://orcid.org/0000-0002-2388-8677)
Institutions
- Chicago Department of Public Health (US)
- Ruth M. Rothstein CORE Center (US)
- University of Illinois Chicago (US)
- Development Fund (NO)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1097/qai.0000000000003500
- Citations
- 4
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.17